KRSNAA Krsnaa Diagnostics Q2 FY27 results (Jul–Sep 2026) and concall
Management summary
- Krsnaa Diagnostics delivered strong operational revenue growth of 32% YoY in Q2 FY27 to ₹271 crores and crossed ₹500 crores in half-yearly revenue for the first time (₹507 crores in H1 FY27).
- Profitability saw slight margin compression to 27% EBITDA margin and PAT of ₹25 crores due to upfront operating costs and manpower scaling for new projects, notably Rajasthan.
- A central focus for investors was the elevated receivables balance of ₹470 crores, against which management expects collections of approximately ₹200 crores in Q3 FY27 as state disbursements resume.
Source: Inve concall analysis and management guidance record.
Highlights
-
Revenue from operations grew 32% YoY to ₹271 crores in Q2 FY27 and 27% YoY to ₹507 crores in H1 FY27
-
Retail segment generated ₹23.5 crores in Q2 FY27, up ~35% YoY, with patient volume up 45% and test volume up 48%
-
Promoter group demonstrated confidence through allotment of convertible warrants of ₹92 crores (₹23 crores already contributed)
-
Strategic expansion in cash-based PPPs (HP CT 34 machines and Punjab PET-CT tenders secured) supporting working capital efficiency
What they filed
Q2 FY27: revenue up 1450.0%, net profit up 8.7% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 10 | 8 | 2 | -3 −133% | -1 −110% | 20 +150% | 31 +1450% |
| EBITDA | 48 | 53 | 50 | 58 | 48 +0% | 57 +8% | 57 +14% | 72 +24% |
| Net profit | 22 | 21 | 20 | 23 | 16 −27% | 43 +105% | 16 −20% | 25 +9% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Revenue
Cash-based Revenue Share Revenue · FY27 · High confidence 40% to 45% (approximately ₹400 crores)
From 35% to 38% today
Retail Revenue Share Revenue · FY27 · High confidence Double-digit contribution
From ~9% today
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Receivables visibility and collection confidence Direct
The amount that I spoke about in terms of confidence is because there are confirmations we've seen on ground coming from the government quarters directly where some of the payments were supposed to hit our accounts even in the last couple of weeks... we see this money to be colle
Receivables of ₹470 crores represent a major working capital stretch; confirmation of ₹200 crores collections expected in Q3 relieves liquidity concerns.
Asked by Dhwanil Desai, Turtle Capital
Decline in revenue per test and test volume drivers Direct
And the price that you saw that the price has lowered is also -- it's a blended price coming from a combination of PPP and retail... on the PPP side, because it's a large project, there because of the PPP prices that we offer in Rajasthan, on a blended basis, you see price coming
Explains the >30% sequential decline in revenue per test as a mix effect driven by high-volume, lower-price Rajasthan pathology deployment.
Asked by Surya Narayan Patra, PhillipCapital India Private Limited
Unlock risks & concerns, Q3 FY27 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 6 risks, concerns & management red flags
- 4 watchlist triggers for Q3 FY27
- +6 more guidance targets & verbatim management quotes
- +4 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





